232 ELEMENTAL IMPURITIES—LIMI - US Pharmacopeia (USP) INTRODUCTION This general chapter specifies limits for the amounts of elemental impurities in drug products Elemental impurities include catalysts and environmental contaminants that may be present in drug substances, excipients, or drug products These impuri-ties may occur naturally, be added intentionally, or be introduced inadvertently (e g , by interactions with processing equip-ment and
US Pharmacopeia (USP) USP is dedicated to helping improve global health through standards setting in compounding, biologics, pharmaceutical manufacturing and other fields
Presentation - US Pharmacopeia (USP) USP NITROSAMINE IMPURITIES JOINT SUBCOMMITTEE (JSC) - JSC CHARGE and Deliverables The JSC charge is the development of a roadmap and guide for USP for developing public standards and assist USP efforts in other activities related to Nitrosamines topics
PHARMACOPOEIAL DISCUSSION GROUP SIGN-OFF DOCUMENT CODE: G-07 NAME . . . NAME: Elemental Impurities It is understood that sign-off covers the technical content of the draft and each party will adapt it as necessary to conform to the usual presentation of the pharmacopoeia in question; such adaptation includes stipulation of the particular pharmacopoeia’s reference materials and general chapters
37(3) In-Process Revision: lt;233 gt; ELEMENTAL IMPURITIES--PROCEDURES BRIEFING 233 Elemental Impurities—Procedures, page 201 of PF 36(1) [Jan –Feb 2010] This revision to the general test chapter, Elemental Impurities—Procedures 233 is based on comments received during the public comment period The Expert Committee on elemental impurities has reviewed these comments and is proposing this revision to provide additional clarity and flexibility Although
USP Authorized Distributors USP Reference StandardsUSP Pharmaceutical Analytical Impurities (PAI) Al Massat Life Sciences – Algeria office 14A Mohamed Bachouche St Al Mouradia – Algeria Tel : +231 550 1483 41 northafrica@al-massat com www al-massat com www maskem com Pharma Global Dept USP Reference StandardsUSP Pharmaceutical Analytical Impurities (PAI) Tunisia
GLP1 Therapies - US Pharmacopeia (USP) Quantitation of Impurities in Tirzepatide Peptide Fragments by High Resolution Ultra-High Pressure Liquid Chromatography-Mass Spectrometry (UHPLC-MS) Regulatory considerations for Setting Smart Starting Material Specifications Risk Assessment for a Nitrosamine Contamination of Peptide APIs Manufactured by Solid-Phase Peptide Synthesis (SPPS)